hyaluronidase

2 phase III randomized controlled trials have shown that a single intravireal injection of vitrase is safe and demonstrated efficacy in aiding clearance of vitreous hemorrhage.

The Vitrase 6,200-unit single-dose vial was discontinued, although Vitrase is still available in 200-U/mL vials.

Vitrase did, however, enable patients to see more clearly.

Although the delay is not terribly helpful it has been done for the very best reasons - to ensure that Vitrase has the best possible chance of being successful, " he said.

Three of the groups will each receive one of three different doses of Vitrase (7.

s) Termination of ISTA Vitrase collaboration agreement (including interest income of $0.

7 million (k) Restructuring charge and related inventory write-offs (l) Transition/duplicate operating expenses (m) ISTA Vitrase collaboration fee (n) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): Tax effect Non-GAAP pre-tax adjustments of $34.

3 million (h) Transition/duplicate operating expenses (i) ISTA Vitrase collaboration fee (j) Tax effect for non-GAAP adjustments "GAAP" refers to financial information presented in accordance with generally accepted accounting principles in the United States.

1) million (d) Unrealized loss on the mark-to-market adjustment to derivative instruments (e) Income from revised Vitrase collaboration agreement with ISTA pharmaceuticals (f) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): Tax effect Non-GAAP pre-tax adjustments of $7.

3 million (d) Interest income related to previously paid state income taxes and reversal of interest expense related to tax settlements (e) Unrealized gain on the mark-to-market adjustment to derivative instruments (f) Termination of ISTA Vitrase collaboration agreement (including interest income of $0.

0 (e) Patent infringement settlement (f) Income tax benefit for previously paid state income taxes and tax effect for non-GAAP adjustments (g) ISTA Vitrase collaboration fee ALLERGAN, INC.

On June 7th, ISTA announced FDA approval of Istalol for glaucoma, which is the company's second FDA approval; the company announced FDA approval for Vitrase as a spreading agent in May.

Vitrase has received "fast-track" designation from the FDA for the treatment of vitreous hemorrhage.